Akero Shows More Strong Fibrosis Data, But Analysts Cite Safety Worry

 
• By Joseph Haas
  
Female person holding red human liver model at white body
Akero's 96-week data shows sustained, expanded benefit in MASH
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business